

Probabilistic Index Models for testing differential gene expression in single cell RNA-seq data

Alemu Takele Assefa^{†1}, Jo Vandesompele^{‡1}, Olivier Thas^{§,1,2,3} ¹Ghent University, Belgium; ²University of Wollongong, Australia; ³Hasselt University, Belgium [†]AlemuTakele.Assefa@UGent.be, [‡]Jo.Vandesompele@UGent.be, [§]Olivier.Thas@UGent.be

March 26, 2019







1 / 17

March 26, 2019

Assefa, AT (Ghent University)

ENAR 2019 Conference

Single cell RNA sequencing (scRNA-seq) data

- profiles gene expression patterns in individual cells
- data typically presented in a matrix

	cell 1	cell 1	• • •	$_{ m cell} n$
gene 1	y_{11}	y_{12}		y_{1n}]
gene 2	y_{21}	y_{22}		y_{2n}
÷		:	·	:
$_{\rm gene}G$	$\lfloor y_{G1}$	y_{G2}		y_{Gn}
	$[N_1$	N_2		N_n]

from statistical point of view

- opportunity: high number of cells
- challenge: high noise level from various sources
 - technical noise because of low input material
 - intrinsic biological variability

 \Rightarrow scRNA-seq data

- sparse data
- complex distribution of gene expression

DGE in scRNA-seq

 \Rightarrow identifies a set of genes with different distribution of expression across groups of cells

- parametric methods are often used for testing DGE e.g. NB or ZINB models
 - + are flexible and easy for interpretation
 - + account for various sources of variation
 - + adaptable to many experimental design
- parametric assumptions do not always hold
 ⇒ tools relying on such assumption may thus under-perform

Benchmarking result by Soneson et al. Nature methods (2018)



- methods for bulk RNA-seq also work
- simple methods, such as t-test, WMW show good performance

non-parametric tools for testing DGE in scRNA-seq data

- showed better performance than many of the parametric tools but
- have limited scope
- no interpretable measure of fold-change (effect size)

Therefore, we suggest Probabilistic Index Models $(PIM)^1$ to widen the scope of non-parametric tools while

- being robust
- can be used for simple and complex experimental designs
- provide interpretable measure of the effect size

¹Thas et al. JRSS-B (2012)

Assefa, AT (Ghent University)

ENAR 2019 Conference

March 26, 2019 5 / 17

In PIM, we model the conditional probability

$$P(Y_{gi} \leq Y_{gj} | X_i, X_j) = P(Y_{gi} < Y_{gj} | X_i, X_j) + \frac{1}{2} P(Y_{gi} = Y_{gj} | X_i, X_j)$$

where Y_{gi} and Y_{gj} are the gene expression of gene g in cell i and j with their corresponding covariate information X_i and X_j , resp.

 $P(Y_{gi} \leq Y_{gj} | X_i, X_j)$ is called the Probabilistic Index (PI)

PIM

• using a function m(.) with range [0, 1], we model the PI as a function of X,

$$\mathbf{P}(Y_{gi} \preceq Y_{gj} | X_i, X_j) = m(X_i, X_j; \beta_g)$$

 $m(X_i, X_j; \beta_g)$ satisfies some particular restrictions, see Thas et al. (2012)

- the parameter β_g represents the effect of X on the PI
- with an appropriate link function g(.), such as logit,

$$m(X_i, X_j; \beta_g) = g^{-1}(Z_{ij}^T \beta_g)$$

where $Z_{ij} = X_j - X_i$ – one possible choice

Example

Let $(Y_{gi}, X_i), i = 1, ..., n$ are *n* i.i.d. r.v., where Y_{gi} is the normalized gene expression of gene *g* in cells *i* and X_i is a treatment group indicator of cell *i* $(X_i = 1 \text{ for treatment and } 0 \text{ for control}).$

Therefore, with a logit link function, we define PIM as

logit {P($Y_{gi} \preceq Y_{gj} | X_i, X_j$)} = $\beta_g(X_j - X_i)$

• if $\beta_g = 0$, $P(Y_{gi} \leq Y_{gj} | X_i = 0, X_j = 1) = 0.5$

⇒ probability that expression of gene g in a randomly selected cell from the control group is smaller than that of a randomly selected cell from the treatment group is 50% (and vice versa)

•
$$P(Y_{gi} \preceq Y_{gj} | X_i = 0, X_j = 1) = \frac{e^{\beta_g}}{1 + e^{\beta_g}} \in [0, 1]$$

Example ... cont'd

• parameter estimation equation (score function)

$$\sum_{(i,j)\in I_n} \mathcal{A}(\mathcal{Z}_{ij};\beta) \left\{ I_{ij} - g^{-1}(\mathcal{Z}_{ij}^T\beta) \right\} = 0$$

where $I_{ij} = I(Y_i < Y_j) + 0.5I(Y_i = Y_j) \in (0, 0.5, 1)$ – pseudo observations

- testing for no treatment effect, $H_0: \beta_g = 0$, \Rightarrow using Wald test of Thas et al $(2012)^2$
- treatment effect size \Leftrightarrow PI

$$\hat{\mathbf{P}}(Y_{gi} \preceq Y_{gj} | X_i = 0, X_j = 1) = expit\{\hat{\beta}_g\} \in [0, 1]$$

Testing DGE for G >> 1 genes results in a vector of p-values
 ⇒ Benjamini-Hochberg procedure to control false discovery rate (FDR)

²Thas et al. JRSS-B (2012)

Assefa, AT (Ghent University)

Example: testing for DGE using PIMs

- Data:
 - Neuroblastoma cell line scRNA-seq data (SMARTer/C1)
 - two groups of cells: nutlin-3 treated $(n_1=31)$ and control $(n_2=52)$
 - all cells came from a single biological sample and processed in a single batch
 - $\approx 12,000$ genes, each with expression in at least 5 cells
- Objective: testing for DGE between nutlin-3 treated and control group of cells (X) adjusting for library size (N)
- PIM specification

$$\operatorname{logit}\{ P(Y_{gi} \leq Y_{gj} | X_i, X_j, N_i, N_j) \} = \underbrace{\beta_g^X(X_j - X_i)}_{\operatorname{treatment effect}} + \underbrace{\beta_g^N(\log N_j - \log N_i)}_{\operatorname{adjust for library size}}$$

Example: testing for DGE using PIMs ... cont'd

• PIM specification

$$\operatorname{logit} \{ \operatorname{P}(Y_{gi} \preceq Y_{gj} | X_i, X_j, N_i, N_j) \} = \underbrace{\beta_g^X(X_j - X_i)}_{\operatorname{treatment effect}} + \underbrace{\beta_g^N(\log N_j - \log N_i)}_{\operatorname{adjust for library size}}$$

• the effect of nutlin-3 treatment for gene g given $N_i = N_j = n$,

$$logit\{P(Y_{gi} \leq Y_{gj} | X_i = 0, X_j = 1, N_i = n, N_j = n)\} = \beta_g^X$$

• ranking genes based on their estimated marginal PI of nutlin-3, i.e.

left edge	middle	right edge
$\mathrm{PI} \to 0$	$\mathrm{PI} \approx 0.5$	$\mathrm{PI} \rightarrow 1$
down regulated	no DGE	up regulated

Example: testing for DGE using PIMs ... results



Two sets of simulation methods

Splat simulation³: gamma-Poisson hierarchical model
 ⇒ Negative Binomial

- \Rightarrow fast and several scenario can be simulated
- emi-parametric simulation

 \Rightarrow sampling new data from the actual distribution of a real scRNA-seq data

 \Rightarrow involves two steps: construct density, and sample from the constructed density

 \Rightarrow generates realistic data

³Zappia et al Genome Biology (2017)



Assefa, AT (Ghent University)

ENAR 2019 Conference

March 26, 2019 14 / 17

Performance evaluation ... simulation results



sim. design: 5000 genes, 2 group of cells $(n_1 = n_2 = 50)$, 10% DE genes, source data generated using SMARTer/C1 protocol, gene expression data in terms of read-counts. Assefa, AT (Ghent University) ENAR 2019 Conference March 26, 2019 15 / 17

Performance evaluation ... simulation results



sim. design: 5000 genes, 2 group of cells $(n_1 = n_2 = 100)$, 10% DE genes, source data generated using Chromium (10x Genomics) protocol, gene expression data in terms of UMI-counts. Assefa, AT (Ghent University) ENAR 2019 Conference March 26, 2019 16 / 17

- requires minimal distributional assumption \Rightarrow robust
- generalization of non-parametric methods
 ⇒ can be used for simple and complex experimental designs
 ⇒ PIM is more flexible than SAMSeq⁴
- interpretable effect size in terms of PI
 ⇒ meaningful gene ranking based on PI (in combination with p-values ot its standard error)
- valid under the presence of tied observations
- can be used for different measures of gene expression, such as read-counts and UMI-counts

⁴Li et al, Statistical methods in medical research (2013)

Assefa, AT (Ghent University)

ENAR 2019 Conference